secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001628280-22-022329
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci Q2 net loss $28.7M, exceeds Active Program guidance, restructures to extend cash to late-2025
--------------------------------------------------------------------------------

- Net loss of $28.7M in Q2 2022, compared to $41.2M loss in Q2 2021.
- Cash and equivalents $206.0M as of June 30, 2022, down from $252.6M at Dec 31, 2021; 2022 cash decrease expected ~$110M.
- Signed ten new Active Programs year-to-date, exceeding full-year guidance of at least eight; total now 19.
- Strategic reorganization reduces headcount and extends cash runway into late 2025; workforce reduction included.
- Entered multi-program collaboration with undisclosed biotech for antibody-drug conjugates using Bionic technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828022022329/0001628280-22-022329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828022022329/absc-20220811.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-022329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer